PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223434
PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1223434
Middle East and Africa acute myeloid leukemia diagnostics market is projected to register a substantial CAGR of 9.0% in the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022, and the forecast period is 2023 to 2030.
Market Segmentation
Middle East and Africa Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing, and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), Monocytic (M5), Erythroleukemia (M6), and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, and 65 and Above), Gender (Male and Female), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (South Africa, Saudi Arabia, UAE, Egypt, Israel, and Rest of Middle East and Africa) Industry Trends and Forecast to 2030.
A rise in healthcare expenditure for cancer diagnosis and treatment
Novel technological advancements in leukemia diagnostics
Market Players
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific, Inc.
QIAGEN
Abbott
Siemens Healthcare GmbH
Merck KGAA
Hologic, Inc.
Agilent Technologies, Inc.
DiaSorin S.p.A.
Illumina, Inc.
BIOMERIEUX